Compared with other animals, rabbits have a unique process of B cell development and are farther apart than rodents and humans. In addition, rabbit B cells have a dual affinity maturation mechanism, including gene conversion and SHM (somatic hypermutation). At the same time, the protein structure of rabbit IgG is different from that of mouse IgG, which is reflected in that it has only one subtype of IgG and its CDR3 region is longer than mouse CDR3. These differences make rabbit produce monoclonal antibodies with higher affinity and specificity.

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. We plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. Currently, we have developed over 1000 monoclonal antibodies for cancer targets. Scientists can skip the tedious steps of antibody development and screening. They can have more time to study the biological mechanism and developability of drug targets, thus accelerating the process of new drug R&D.

DIMA’s rabbit monoclonal antibodies are developed using our own proprietary DimAb^® monoclonal antibody development platform. All our antibodies are raised against the potential diagnostic, prognostic and therapeutic targets. We used functional proteins as antigens and verified the antibodies with various applications and protein samples. Most of our monoclonal antibodies show comparable or better specificities and affinities comparing to the reference antibodies. In addition to the specificity and affinity, DIMA’s recombinant monoclonal antibodies also show high level of batch-to-batch consistency, because our single B cell cloning technology can directly isolate IgG gene from positive rabbit B cells, which significantly lower risk of the loss of hybridoma cells.  

Product Advantage:

High affinity and high specificity